论文部分内容阅读
目的探讨血清可溶性E-钙黏蛋白和血浆骨桥蛋白(OPN)在宫颈癌新辅助化疗(NACT)前、后的表达变化,评价两者联合检测对宫颈癌新辅助化疗敏感性及疗效评价的价值。方法采用双抗体夹心法酶联免疫吸附试验测定50例宫颈癌患者NACT前、后血清可溶性E-钙黏蛋白和血浆OPN含量,同时根据化疗疗效将患者分为NACT有效组及NACT无效组,统计分析NACT治疗前、后血清可溶性E-钙黏蛋白和血浆OPN含量与宫颈癌NACT敏感性及化疗疗效的关系。结果 NACT治疗后患者的血清可溶性E-钙黏蛋白和血浆OPN表达水平均明显下降(P<0.05)。NACT治疗前、后NACT有效组血清可溶性E-钙黏蛋白和血浆OPN表达水平均明显低于NACT无效组(P<0.05)。NACT治疗前、后血清可溶性E-钙黏蛋白和血浆OPN表达水平变化与化疗疗效呈显著正向线性相关关系(P<0.05)。结论宫颈癌患者血清可溶性E-钙黏蛋白和血浆OPN表达水平与NACT敏感性及化疗疗效关系密切,有望作为一种新的血液学指标评价NACT敏感性及化疗疗效,为宫颈癌的临床个体化治疗及化疗方案制定提供参考。
Objective To investigate the expression changes of serum soluble E-cadherin and osteopontin (OPN) in cervical cancer before and after neoadjuvant chemotherapy (NACT), and to evaluate the sensitivity and efficacy of the combined detection of neoadjuvant chemotherapy and cervical cancer value. Methods Serum levels of soluble E-cadherin and plasma OPN in 50 patients with cervical cancer before and after NACT were determined by double antibody sandwich enzyme-linked immunosorbent assay (ELISA). At the same time, patients were divided into NACT group and NACT group according to chemotherapy efficacy To analyze the relationship between serum soluble E-cadherin and plasma OPN levels and NACT sensitivity of cervical cancer and the curative effect of chemotherapy after NACT treatment. Results Serum levels of soluble E-cadherin and plasma OPN were significantly decreased in patients treated with NACT (P <0.05). The levels of serum soluble E-cadherin and plasma OPN in NACT-treated group before and after NACT treatment were significantly lower than those in NACT-ineffective group (P <0.05). The changes of serum soluble E-cadherin and plasma OPN levels before and after NACT showed a significant positive linear correlation (P <0.05). Conclusions Serum levels of soluble E-cadherin and plasma OPN in patients with cervical cancer are closely related to the sensitivity of NACT and the curative effect of chemotherapy. It is expected to be a new hematological index to evaluate the sensitivity of NACT and the curative effect of chemotherapy. It is the clinical individualization of cervical cancer Treatment and chemotherapy program to provide a reference.